Caring for life scientifically, developing science with a humanistic attitude
Leading molecular diagnostics provider in the oncology field
Introduction to Shanghai Saim Bio-Medical Technology Co., Ltd.
Shanghai Saim Bio-Medical Technology Co., Ltd. is a high-tech enterprise engaged in scientific research, product development, and clinical services in the biomedical field, focusing on providing "personalized treatment" services for cancer patients based on molecular diagnostics.
Saim Technology has established strategic partnerships with the Shanghai Institute of Life Sciences of the Chinese Academy of Sciences, the Institute of Life Sciences of Fudan University, the Pathology Diagnostic Center of Fudan University, and other leading biomedical research institutions in China. It also collaborates with world-class biomedical laboratories in the United States and Europe to continuously advance molecular diagnostic technologies, providing scientific support for personalized treatment.
While advancing technology, Saim is committed to establishing a comprehensive molecular diagnostic technology and service system for the Chinese population in the oncology field, providing complete, scientific, accurate, and convenient personalized treatment services from the patient's perspective with a humanistic attitude. Saim's personalized treatment services include not only a rigorous scientific management system and a strict quality assurance system but also a humanized service system to ensure a pleasant experience for patients.
The company's main business segments include molecular diagnostics, development of diagnostic kit products, construction and development of tumor tissue specimen banks, collaborative research and development in biomedical technology, and sales of pharmaceuticals and medical devices.
The company maintains close ties with affiliated hospitals of Fudan University, Shanghai Jiao Tong University, Second Military Medical University, Sun Yat-sen University, and other universities in Guangdong, cooperating with more than 60 tertiary hospitals, and this number is growing rapidly. The company has stable and comprehensive clinical sample collection channels and can provide tumor tissue specimens that meet project research requirements. The company has long focused on the collection of specimens for high-incidence tumors in the Chinese population, especially the collection and organization of family pedigrees of Chinese cancer patients, such as liver cancer pedigrees and colorectal cancer pedigrees, among which some pedigrees have been traced for four generations and are under follow-up. At the same time, the company is actively conducting verification research in the Chinese population based on the latest clinical progress in high-incidence tumors in foreign populations. Currently, the company has established long-term friendly cooperative relationships with multiple tertiary hospitals.
Saim's development goal is to become a leader in personalized treatment in the oncology field in China, striving to achieve annual sales revenue exceeding 100 million yuan within five years of development.
Company address: 1st Floor, Wensheng Building, 1888 Hutai Road, Shanghai
Transportation: Metro Line 7, Dachangzhen Station, Exit 2 / Bus 702, 68, 767B, 767
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows